Buyout at latest would be post FDA approval. FDA approval is authorization to sell the device. My planned exit (at the latest) would be expected liquidity event if FDA approves IDE application for human trials. That would be a short term pop before settling back to reality cuz there will be another offering to fund human trials, at which point I'd likely buy back in. Buyout at a minimum would require positive human trial data vs. competitive treatments. My guess is RDGL wouldn't entertain offers until FDA approved. Either way, any buyout would be long after IDE approval pop.
News 
Market Data 
Discover 
AI
